| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100792 | Journal of Crohn's and Colitis | 2009 | 8 Pages |
Abstract
These results provides a mechanistic rationale for both the failure of lenalidomide (CC-5013) in a recent randomised controlled trial in Crohn's disease, and for the evaluation of CC-10004 as a novel oral therapy in the treatment of CD and UC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
J.N. Gordon, J.D. Prothero, C.A. Thornton, K.M. Pickard, A. Di Sabatino, P.M. Goggin, S.L. Pender, T.T. MacDonald,